Market News / Story
CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
Stocktwits ·
Stocktwits reports: Shares of Capricor Therapeutics rose 5% on Wednesday after the company presented clinical data from the trials of its experimental cell therapy Deramiocel for Duchenne muscular dystrophy, including stabilization of heart function in boys who already had heart damage, in addition to previously announced improvements in limb function. Duchenne muscular dystrophy is a severe, progressive genetic disorder that causes muscle degeneration and weakness, starting with the limbs…